End-Stage Renal Disease Market - Growth, Trends, and Forecasts (2023-2028)

The end-stage renal disease market is expected to witness a CAGR of around 10% during the forecast period.

The COVID-19 pandemic forced unprecedented changes in the daily life of people. Many patients were under lockdown during this time, and the nephrology community was forced to adapt quickly to this new reality. Patients on dialysis were at high risk of COVID-19 exposure due to the widespread use of public transportation and densely packed clinical spaces. For instance, according to an article published by Karger in June 2022, chronic hemodialysis (HD) patients were considered at high risk of severe COVID-19 with an increased risk of death, and the constraints during the pandemic had an impact on the dialysis delivery to COVID-free hemodialysis patients. Thus the COVID-19 pandemic had a significant effect on the current market initially. However, post-pandemic, the market studied is expected to grow significantly during the forecast period.

The end-stage renal disease market is driven by the increasing number of patients suffering from chronic kidney disease. According to the article published by PubMed Central in April 2022, approximately 10% of the global population suffers from chronic kidney disease, and millions die each year. According to the same article, the rate of patients with chronic kidney disease is increasing.

Another factor is the introduction of technologically advanced products, like low-maintenance dialysis equipment and artificial kidney. In March 2021, Baxter International Inc. announced the United States FDA clearance of its next-generation Artificial Kidney 98 dialysis machine, designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. This indicated that companies are taking initiatives to establish a strong footprint and launch technologically advanced products in the market.

Additionally, there is a higher prevalence rate for diabetes, which leads to cause end-stage renal disease in the long run, which may drive the market growth. According to the International Diabetes Federation, in 2021, around 537 million adults (20-79 years) were living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 by 2045. Diabetes is one of the leading causes of kidney failure, which is likely to drive the market's growth over the forecast period.

Therefore, owing to the factors mentioned above, such as the rising prevalence of diabetes and the introduction of technologically advanced products, the market studied is anticipated to witness growth over the analysis period. However, the delay in diagnosing chronic kidney disease may restrain the market growth over the forecast period.

End-stage Renal Disease Market Trends

Dialysis Segment by Treatment is Expected to Witness a Significant Growth over the Forecast Period

Dialysis is a procedure that removes waste products from the blood, such as urea and creatinine, as a result of impaired kidney function. It is frequently required for persons with chronic renal failure. The blood is cleansed, and extra fluid and toxins are eliminated during this operation.

Moreover, the demand for dialysis is expected to increase as the incidence of end-stage renal disease increases worldwide. The prevalence of end-stage renal disease (ESRD) is high and growing at a significant rate. According to the article published by the National Institute of Health (NIH) in 2021, nearly 786,000 people in the United States were living with ESRD, with 71% on dialysis and 29% with a kidney transplant. Meanwhile, the number of patients who initiated peritoneal dialysis and received a preemptive transplant reached an all-time high of 18,631. According to the American Society of Nephrology, funding for dialysis is rising in the United States.

The end-stage renal disease market is growing as the population increases globally, thus, raising funding for better dialysis products and services. For instance, on July 1, 2021, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule for the Prospective Payment System (PPS) for renal dialysis services. Under the ESRD PPS for 2022, Medicare is expected to pay USD 8.9 billion to approximately 7,700 ESRD facilities for furnishing renal dialysis services.

On the other hand, factors like the high prevalence of diabetics, hypertension, rising incidences of kidney failures, lack of kidney donors for transplantation, tedious kidney transplant procedure, and increasing demand for home peritoneal dialysis treatment drive the segmental growth over the forecast period.

Asia-Pacific is is Expected to Witness a High Growth over the Forecast Period

Asia-Pacific is expected to witness high growth in end-stage renal disease due to the presence of high disposable income and the high acceptance rate of technologically improved products. Moreover, high blood pressure and diabetes cases in the region may contribute to the market growth. According to the data from the International Diabetes Federation in December 2021, an estimated 90 million adults were living with diabetes in the South-East Asia (SEA) region in 2021. This is estimated to increase to 113 million by 2030 and 152 million by 2045. Moreover, according to the same source, 46 million adults living with diabetes in the IDF SEA Region are undiagnosed, accounting for 51% of the total number of adults living with diabetes in the region.

Additionally, growing patient affordability, an aging population, lifestyle stress, a broad population base, and improving diagnosis quality are expected to fuel market growth. According to a report published by the national health portal of the Indian Government in July 2022, it is estimated that every year about 2.2 lakh new patients of end-stage renal disease (ESRD) are increasing, resulting in demand for 3.4 crore dialysis every year. Approximately 4,950 dialysis centers were available, largely in the private sector in India. The presence of a large number of dialysis centers in this region and a rise in the number of patients with chronic renal and kidney diseases are expected to boost the market growth.

End-stage Renal Disease Market Competitor Analysis

The market studied is fragmented due to the presence of many major market players. Market players adopt the strategies, such as organic growth strategies (treatment type launches, treatment type approvals) and others (such as patents and events), which are prioritized by corporations with inorganic growth strategies, like acquisitions, partnerships, and collaborations. Some market players are Nipro Corporation, Fresenius SE & Co. KGaA, Baxter International Inc., Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical, Nikkiso Co., etc.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.